The overall survival (OS) in the pooled studies at one year after the start of treatment was 82% in patients treated with lenalidomide/dexamethasone versus 75% in patients treated with placebo/dexamethasone, with a median follow-up duration of 98.0 weeks (min:
Egy évvel a kezelés kezdete után az összesített túlélés (overall survival, OS) 82% volt a lenalidomid/ dexametazonnal kezelt és 75% a placebo / - dexametazonnal kezelt betegek esetén, 98, 0 hét (min: